Literature DB >> 33403618

A rare cause of acute kidney injury with chronic myelomonocytic leukemia.

Marina Asano1, Hanako Hase2, Yuki Naruse2, Kyogo Kawada2, Iori Kojima3, Joel Branch4, Hiroshi Kitamura5, Hideaki Shimizu2.   

Abstract

An 80-year-old man with myelodysplastic syndrome developed acute kidney injury (AKI) and peripheral blood monocyte-dominant leukocytosis. Glomerular disease was suspected from urinalysis, which showed proteinuria and microscopic hematuria with red cell casts. Eventually, he died of respiratory failure, after which a postmortem was performed. In the glomeruli, the extracapillary space was filled with numerous mononuclear cells and erythrocytes. At first interpretation, the glomerular findings appeared to represent cellular crescents. However, immunostaining revealed that the extracapillary mononuclear cells were in fact leukemic cells. Furthermore, tubular injury due to marked accumulation of lysozyme was also recognized together with infiltration of leukemic cells in the interstitium. The diagnosis of kidney infiltration by chronic myelomonocytic leukemia (CMML) and lysozyme-induced tubular injury was eventually made. Our case is the first report showing extracapillary infiltration of leukemic cells by immunostaining. In addition, lysozyme-induced tubular injury is a forgotten cause of kidney injury in patients with CMML. This case teaches us the rare and forgotten causes of AKI with CMML.
© 2021. Japanese Society of Nephrology.

Entities:  

Keywords:  Acute kidney injury; Chronic myelomonocytic leukemia; Extracapillary infiltration; Lysozyme-induced tubular injury

Year:  2021        PMID: 33403618     DOI: 10.1007/s13730-020-00567-6

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  11 in total

Review 1.  Kidney involvement in leukemia and lymphoma.

Authors:  Randy L Luciano; Ursula C Brewster
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

2.  [Lysozyme-induced nephropathy: A rare cause of renal failure in chronic myelomonocytic leukemia].

Authors:  Gwladys Robinet-Zimmermann; Nathalie Rioux-Leclercq; Thierry Frouget; Cécile Le Naoures
Journal:  Ann Pathol       Date:  2020-05-19       Impact factor: 0.407

3.  Myeloproliferative neoplasms cause glomerulopathy.

Authors:  Samar M Said; Nelson Leung; Sanjeev Sethi; Lynn D Cornell; Mary E Fidler; Joseph P Grande; Sandra Herrmann; Ayalew Tefferi; Vivette D D'Agati; Samih H Nasr
Journal:  Kidney Int       Date:  2011-06-08       Impact factor: 10.612

Review 4.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-06       Impact factor: 10.047

5.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

6.  Glomerular injury in chronic myelomonocytic leukemia.

Authors:  F Morschhauser; E Wattel; D Pagniez; V Lovi; C Rose; F Bauters; P Fenaux
Journal:  Leuk Lymphoma       Date:  1995-08

7.  Severe renal complications in chronic myelomonocytic leukemia.

Authors:  R Enriquez; A E Sirvent; F Marin; M Perez; M R Alpera; F Amorós
Journal:  J Nephrol       Date:  2008 Jul-Aug       Impact factor: 3.902

8.  Lysozyme-Induced Nephropathy.

Authors:  Dominick Santoriello; Laurie May Andal; Robert Cox; Vivette D D'Agati; Glen S Markowitz
Journal:  Kidney Int Rep       Date:  2016-09-09

9.  Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia.

Authors:  E F Osserman; D P Lawlor
Journal:  J Exp Med       Date:  1966-11-01       Impact factor: 14.307

10.  An unexpected complication of chronic myelomonocytic leukemia: severe renal failure due to malignant tubulo-interstitial cell infiltration.

Authors:  Jerrold Spapen; Karel Fostier; Hendrik De Raeve; Peter Janssens; Herbert Spapen
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.